Beam Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

BEAM$25.15-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2023	81,632,496	$816	$2,169,798	$604	$(1,189,889)	$981,329
Purchase of common stock under ESPP	76,461	1	1,397	—	—	1,398
Vesting of restricted common stock	420,579	4	(4)	—	—	—
Stock-based compensation	—	—	29,281	—	—	29,281
Exercise of common stock options	151,291	2	1,674	—	—	1,676
Other comprehensive income (loss)	—	—	—	(1,525)	—	(1,525)
Net loss	—	—	—	—	(98,669)	(98,669)
Balance at March 31, 2024	82,280,827	$823	$2,202,146	$(921)	$(1,288,558)	$913,490
Vesting of restricted common stock	72,040	1	(1)	—	—	—
Stock-based compensation	—	—	31,604	—	—	31,604
Exercise of common stock options	33,343	—	240	—	—	240
Other comprehensive income (loss)	—	—	—	(189)	—	(189)
Net loss	—	—	—	—	(91,051)	(91,051)
Balance at June 30, 2024	82,386,210	$824	$2,233,989	$(1,110)	$(1,379,609)	$854,094
Purchase of common stock under ESPP	58,726	1	1,223	—	—	1,224
Vesting of restricted common stock	82,739	1	(1)	—	—	—
Stock-based compensation	—	—	29,559	—	—	29,559
Exercise of common stock options	31,208	—	239	—	—	239
Other comprehensive income (loss)	—	—	—	2,869	—	2,869
Net loss	—	—	—	—	(96,668)	(96,668)
Balance at September 30, 2024	82,558,883	$826	$2,265,009	$1,759	$(1,476,277)	$791,317

Condensed Consolidated Statements of Stockholders’ Equity - Continued

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’
	Shares	Amount	Capital	Income (Loss)	Deficit	Equity
Balance at December 31, 2024	83,633,069	$836	$2,298,661	$679	$(1,566,631)	$733,545
Purchase of common stock under ESPP	90,436	1	1,500	—	—	1,501
Issuance of common stock and pre-funded warrants, net of issuance costs of $30.8 million	16,151,686	162	470,316	—	—	470,478
Vesting of restricted common stock	607,196	6	(6)	—	—	—
Stock-based compensation	—	—	26,682	—	—	26,682
Exercise of common stock options	74,707	1	718	—	—	719
Other comprehensive income (loss)	—	—	—	(519)	—	(519)
Net loss	—	—	—	—	(109,270)	(109,270)
Balance at March 31, 2025	100,557,094	$1,006	$2,797,871	$160	$(1,675,901)	$1,123,136
Issuance of common stock and pre-funded warrants, net of issuance costs of $30.8 million	—	—	(4)	—	—	(4)
Vesting of restricted common stock	81,163	1	(1)	—	—	—
Stock-based compensation	—	—	24,367	—	—	24,367
Exercise of common stock options	120,491	1	1,754	—	—	1,755
Other comprehensive income (loss)	—	—	—	(150)	—	(150)
Net loss	—	—	—	—	(102,291)	(102,291)
Balance at June 30, 2025	100,758,748	$1,008	$2,823,987	$10	$(1,778,192)	$1,046,813
Purchase of common stock under ESPP	84,272	1	1,262	—	—	1,263
Vesting of restricted common stock	95,580	1	(1)	—	—	—
Stock-based compensation	—	—	22,747	—	—	22,747
Issuance of common stock for acquisition	403,128	4	6,711	—	—	6,715
Exercise of common stock options	18,037	—	412	—	—	412
Other comprehensive income (loss)	—	—	—	780	—	780
Net loss	—	—	—	—	(112,728)	(112,728)
Balance at September 30, 2025	101,359,765	$1,014	$2,855,118	$790	$(1,890,920)	$966,002

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.